Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGP-15 for non-ischemic dilated cardiomyopathy
ACTRN12616000482460Phase 2Withdrawn
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BGP-15 in dilated cardiomyopathy (DCM) (5 arms), sponsored by Baker Heart and Diabetes Institute. Primary endpoint: Safety and tolerability. Planned start Jun 2016; status: withdrawn.
02
Drugs
BGP-15
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on ACTRN12616000482460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000482460.